A patient in status epilepticus should receive

A. Lorazepam (Ativan), IV: Intravenous lorazepam is the first-line treatment for status epilepticus due to its rapid onset, high efficacy, and relatively long duration of action in terminating active seizures. IV administration allows immediate therapeutic blood levels, which is critical in life-threatening seizure activity. B. Neurontin (Gabapentin), per rectum: Gabapentin is not indicated for acute seizure termination. Its onset of action is slow, and rectal administration is unconventional, making it ineffective in status epilepticus. It is primarily used for chronic seizure prophylaxis and neuropathic pain. C. Lamictal (Lamotrigine), PO: Oral lamotrigine is unsuitable for acute management because it has a slow onset of action and is designed for long-term seizure control. It cannot rapidly terminate active status epilepticus. D. Diazepam (Valium), sublingual: Sublingual administration of diazepam is not standard practice for status epilepticus. While IV or rectal diazepam can be effective, sublingual absorption is unpredictable and too slow to address emergent seizure activity.